Effect of psoralen on the proliferation and cell cycle regulation of prostate cancer LNCaP-AI cell as well as its expression of estrogen-related receptor β

doi:10.3877/cma.j.issn.2095-1221.2018.01.001

Abstract

Abstract:

Objective

To explore the effect of psoralen on the proliferation and cell cycle regulation of prostate cancer LNCaP-AI cellas well as its expression of estrogen-related receptor β.

Methods

LNCaP-AI cells were subjected to treatment with different concentrations of Psoralen in vitro. The proliferation, expression of Ki67 protein, cell cycles and expression of estrogen-related receptor β (ER β) mRNA of LNCaP-AI cells were detected with CCK-8 test, Western blotting, flow cytometry assay and real-time quantitative RT-PCR, respectively.

Results

CCK-8 test showed that psoralen significantly inhibited the proliferation of LNCaP-AI cells in a dose-and time-dependent manner. After treatment with different concentrations of psoralen (30, 50 or 100 μg/ml) for 48 h, LNCaP-AI cells down-regulated expression of Ki67 protein by Western blotting (F = 28.59, P < 0.01). Meanwhile, more cells were arrested at G1 and G2 stage but fewer at S stage as shown by flow cytometry (F = 38.26, 216.634, 153.584, P < 0.01 for all). In addition, increased transcription of ERβ mRNA in LNCaP-AD cells was verified by real-time quantitative RT-PCR (F = 264.09, P < 0.01).

Conclusion

Psoralen can inhibit the proliferation of LNCaP-AI cells and Ki67 expression. The possible mechanism may include inducing cell-cycle arrest at G1, G2 stage and the up-regulation of ERβ mRNA expression in LNCaP-AI cells.

Key words: Psoralen, Prostate cancer, LNCaP-AI, Ki67, Estrogen-related receptor

Shaopeng Li, Jiantong Cai, Mingfang Weng, Hanlin You, Shushang Chen, Weizhen Wu. Effect of psoralen on the proliferation and cell cycle regulation of prostate cancer LNCaP-AI cell as well as its expression of estrogen-related receptor β[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2018, 08(01): 1-5.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2018.01.001

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2018/V08/I01/1

Figures/Tables 5

References 20

1	Ma L, Liu W, Sun F. Primary malignant melanoma of the prostate[J]. Int J Urol, 2010, 17(1):94-95.
2	Zarour L, Alumkal J. Emerging therapies in castrate-resistant prostate cancer[J]. Curr Urol Rep, 2010, 11(3):152-158.
3	Li LC, Chui R, Nakajima K, et al. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression[J]. Cancer Res, 2000, 60(3):702-706.
4	Hariri W, Sudha T, Bharali DJ, et al. Nano-targeted delivery of toremifene, an estrogen receptor-alpha blocker in prostate cancer[J]. Pharm Res, 2015, 32(8):2764-2774.
5	Nelson AW, Tilley WD, Neal DE, et al. Estrogen receptor beta in prostate cancer: friend or foe?[J]. Endocr Relat Cancer, 2014, 21(4):T219-234.
6	孔德玉，杨冬梅，陈艳媛. 雄激素非依赖性前列腺癌LNCaP-AI细胞亚系模型的建立[J]. 吉林医药学院学报, 2012, 33(6):361-363.
7	韩阳军，王冰，蒙学冰. SATB1在人不同前列腺癌细胞系中表达的实验研究[J]. 中国性科学, 2016, 25(6):5-8.
8	赵丕文，牛建昭，王继峰, 等. 补骨脂素的植物雌激素作用及其机制探讨[J]. 中国中药杂志, 2008, 33(1):59-63.
9	Shi XB, Ma AH, Tepper CG, et a1. Molecular alterations associated with LNCaP cell progression to androgen independence[J]. Prostate, 2004, 60(3):257-271.
10	陈书尚，翁明芳，王水良, 等. 补骨脂素对前列腺癌LNCap-AD细胞增殖的影响及其分子机制研究[J/CD]. 中华细胞与干细胞杂志(电子版), 2017, 7(4):219-223.
11	Petric M, Martinez S, Acevedo F, et a1. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy[J]. Asian Pac J Cancer Prey, 2014, 15(23):10277-10280.
12	Ji Y, Zheng M, Ye S, et a1. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer[J]. J Biomed Res, 2014, 28(6):462-467.
13	管若男，范蕾，刘丽娟. TPh对肝癌细胞HepG-2细胞周期、凋亡及相关因子表达的影响[J]. 中国生化药物杂志, 2017, 37(2):15-19.
14	赵万忠，程凯，王晓红, 等. 补骨脂素对乳腺癌耐药细胞株周期和细胞凋亡的影响[J/CD]. 中华临床医师杂志(电子版), 2016(14):2111-2115.
15	Li LC, Chui R, Nakajima K, et al. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression[J]. Cancer Res, 2000, 60(3):702-706.
16	Christoforou P, Christopoulos PF, Koutsilieris M. The role of estrogen receptor beta in prostate cancer[J]. Mol Med, 2014, 20:427-434.
17	Zellweger T, Sturm S, Rey S, et aI. Estrogen receptor beta expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease[J]. Endoe Re1at Caneer, 2013, 20(3):403-413.
18	Kim IY, Seo ND, Kim BC, et a1. Raloxifene, a selective astrogen receptor modulator，induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgenindependent pathway[J]. Cancer Res, 2002, 62(13):3649-3653.
19	Pavese JM, Farmer RI, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein[J]. Cancer Metastasis Rev, 2010, 29(3):465-482.
20	Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy[J]. Arch Intern Med, 2001, 161(9):1161-1172.

基因	引物
ERβ	F:5'-ACCAAAGCATCGGTCACG-3'
?	R:5'-CATGATCCTGCTCAATTCCA-3'
β-actin	5'-GTTGTCGACGACGAGCG-3'
?	R:5'-GCACAGAGCCTCGCCTT-3'

基因	引物
ERβ	F:5'-ACCAAAGCATCGGTCACG-3'
?	R:5'-CATGATCCTGCTCAATTCCA-3'
β-actin	5'-GTTGTCGACGACGAGCG-3'
?	R:5'-GCACAGAGCCTCGCCTT-3'

分组	24 h	48 h	72 h	F值	P值
0 μg/ml	1.00±0.00	1.00±0.00	1.00±0.00	-	-
10 μg/ml	0.92±0.07	0.85±0.07	0.77±0.06	7.61	0.01
30 μg/ml	0.83±0.07	0.78±0.06	0.72±0.06	4.48	0.03
50 μg/ml	0.77±0.09	0.71±0.04	0.66±0.06	4.10	0.04
100 μg/ml	0.71±0.04	0.64±0.05	0.59±0.09	5.28	0.02
F值	17.35	48.49	35.81	?	?
P值	< 0.01	< 0.01	< 0.01	?	?

分组	24 h	48 h	72 h	F值	P值
0 μg/ml	1.00±0.00	1.00±0.00	1.00±0.00	-	-
10 μg/ml	0.92±0.07	0.85±0.07	0.77±0.06	7.61	0.01
30 μg/ml	0.83±0.07	0.78±0.06	0.72±0.06	4.48	0.03
50 μg/ml	0.77±0.09	0.71±0.04	0.66±0.06	4.10	0.04
100 μg/ml	0.71±0.04	0.64±0.05	0.59±0.09	5.28	0.02
F值	17.35	48.49	35.81	?	?
P值	< 0.01	< 0.01	< 0.01	?	?

分组	G1期	S期	G2期
对照组	72.14±0.50	27.57±0.50	0.29±0.07
10 μg/ml	74.57±1.22	23.20±1.39	2.23±0.32
30 μg/ml	78.12±0.92	16.41±1.23	5.47±0.44
50 μg/ml	79.36±0.49	12.23±1.30	8.41±0.95
100 μg/ml	80.60±1.42	7.47±1.03	11.93±0.57
F值	38.26	153.58	216.63
P值	< 0.01	< 0.01	< 0.01

Please choose a citation manager

Content to export